The Hidden Challenges of Chemical Process Scale-Up (And What Actually Helps)
Most scale-up failures are not caused by bad chemistry. The formulation works. The lab results are solid. The team knows what they are doing. What fails is the transition between environments — the move from a controlled bench-scale setting to the commercial conditions that production requires.
Some of the challenges that emerge during that transition are well-documented: non-linear heat transfer, changes in mixing dynamics, reaction kinetics that behave differently at volume.
This post focuses on the challenges that show up less often on standard checklists but can cause problems once scale-up is underway. They are less about chemistry and more about the conditions under which chemistry has to perform: documentation quality, supply chain integrity, knowledge continuity, and partner selection. Recognizing them earlier can make a meaningful difference in production timelines, product quality, and the cost of resolving problems at commercial scale rather than pilot scale.
Valentine Chemicals has been in the chemical business since 1938 and has operated as a contract manufacturer since 1989. Over that time, the company has supported manufacturers across oil and gas, agriculture, water treatment, and specialty chemicals. The challenges below reflect what consistently surfaces in those engagements.
1. The Spec Sheet Written for Lab Conditions, Not Production
Development specifications are typically written to describe what came out of the lab. That is not the same as defining what a production process needs to reliably reproduce.
At bench scale, the chemist is the process. Tolerances that were never formally defined were still maintained, because one person controlled every variable. When that formulation is handed to a production team or a toll partner working from documentation, those informal controls disappear. The specification now has to carry the full weight of process consistency.
The result is a familiar failure mode: disagreements about whether a batch is in spec, not because anyone made an error, but because the specification was never designed for production conditions in. Particle size ranges, moisture content thresholds, viscosity windows, pH tolerances -- if these were acceptable ranges observed during development rather than deliberately defined production targets, they may not reflect what commercial equipment can consistently achieve.
What helps:
Treat specification development as a two-stage process. The development spec describes what was produced in the lab. The production spec defines the acceptable range of process inputs and outputs under commercial conditions, and is written with a production team's review, not just a chemist's. Doing this before the first toll trial is considerably less costly in time, material, and goodwill than reconciling it after.
2. Vendor Handoffs Hidden Inside the Process
Most scale-up risk assessments focus on technical questions: will the process work at volume? The logistical question that receives less attention is: what happens to the material between process steps?
When liquid synthesis happens at one facility, drying at another, and blending or packaging somewhere else, each transfer is a point where variables are introduced and accountability becomes diffuse. Material is exposed to freight handling, temperature shifts, and moisture during transit. Feed properties that were within spec when the material left one site may have drifted by the time it arrives at the next. When something goes wrong in a multi-vendor chain, identifying where the problem entered can be difficult and by the time it is resolved, timelines may have stretched and production windows may have been missed.
This is a structural feature of how many scale-up programs are organized, often by necessity. But the handoff risk is frequently underweighted in project planning because each individual step looks manageable in isolation.
What helps:
Where the process allows, consolidating multiple steps at a single site reduces the number of handoffs and makes troubleshooting more tractable. When synthesis, drying, blending, and packaging happen under one roof, there is no freight exposure between steps, attribution is cleaner, and adjustments can be made across the full process rather than at a single stage.
3. Raw Material Variability That Did Not Exist at Lab Scale
Lab development often uses a single lot of each input material, typically a research-grade lot purchased specifically for the project. The formulation is developed and optimized against that lot. Everything performed as expected, because the inputs were consistent.
At production scale, you are drawing from commercial supply. Different lots, potentially different suppliers, sometimes slightly different grades or purities within specification. A formulation that performed consistently at bench scale can behave differently when a key input varies even slightly -- in particle size distribution, moisture content, trace impurity profile, or viscosity characteristics.
This is not a formulation failure. It is a robustness gap: the formulation was never tested against the natural variation that commercial supply introduces. Teams often do not discover this until they are already in production where batch failures, out-of-spec product, and missed supply commitments are significantly harder to absorb than at pilot scale.
What helps:
Deliberately stress-testing formulations against input variability before committing to a production run. This can mean sourcing input materials from multiple lots or suppliers during late-stage development, or running small-scale trials against different input lots before scaling up. A toll partner who can accommodate that kind of iterative trial work, rather than committing directly to a full production run,can reduce the likelihood of encountering input sensitivity issues mid-production, where the options for recovery are fewest.
4. The Knowledge Transfer Gap
A significant portion of process knowledge at lab scale never makes it into documentation. The development chemist knows which conditions are sensitive without having written them down. They know what was tried, what failed, and what subtle adjustments produced consistent results. That accumulated knowledge shaped the formulation but it lives in their head, not in the spec sheet.
When that formulation is handed to a toll manufacturer, the production team starts from the documentation. They are solving problems the development team already solved, just without the benefit of knowing those problems were solved, or how. Early production runs can cycle through issues that were resolved months earlier during development — consuming time, material, and the goodwill of a partnership that is still getting established.
This gap is structural, not a failure of documentation discipline. Lab notebooks and process reports are not designed to transfer tacit knowledge. But the consequences become visible quickly once production begins.
What helps:
Structured knowledge transfer before the first toll trial -- not a spec handoff, but a working conversation between the development chemist and the production team. That conversation should cover process sensitivities, known failure modes, conditions that produced marginal results, and the informal decisions that shaped the final formulation. Some toll partners actively facilitate this kind of onboarding; others treat the spec sheet as the full brief. It is worth asking how a partner approaches that transition before committing to a first run.
5. QC Gaps Between Development and Production
At lab scale, quality control is close and continuous. A chemist runs the process and evaluates results in real time, using instruments and methods that were calibrated against the formulation they developed. Confidence in the spec is built gradually, through repeated observation of the same chemist, using the same equipment, in the same environment.
At production scale, particularly when working with a toll partner, QC may be separated from the production floor by time, distance, or organizational structure. The instruments used may differ from those in the development lab. The test methods may have been written for different product categories. The tolerances may have been adopted from a similar product rather than validated against this specific formulation.
Teams assume QC continuity because everyone is working from the same specification. But a specification defines target values, it does not guarantee that the measurement methods used to evaluate those values are equivalent across environments. A moisture content of 3% measured with one instrument under one set of conditions may produce a different result than the same measurement taken with different equipment in a different lab.
What helps:
Formalizing QC methodology alignment before any toll trial begins, not just agreeing on target values, but agreeing on how those values will be measured and what instruments and methods will be used. Where possible, choose a toll partner whose quality control lab is physically adjacent to production, so results are available during a run rather than after it. That proximity means process adjustments can be made in real time, rather than after a batch has already been completed.
6. Confidentiality in the Scale-Up Chain
Scale-up typically requires sharing formulation details, process parameters, and IP with multiple parties, including contract development labs, toll manufacturers, packaging vendors, and third-party QC facilities. Technical confidentiality measures like non-disclosure agreements are standard practice, and most organizations apply them without much friction.
Operational confidentiality is less consistently managed. Who on the production floor has access to formulation details. How batch records are stored, for how long, and under what access controls. Whether a toll partner serves direct competitors in the same product category, and if so, how information is separated at an operational level. These are questions that matter, but they tend not to surface until after a relationship is established and IP has already been shared.
A signed NDA is a legal instrument. It documents obligations and assigns liability. It does not, by itself, reflect how confidentiality is actually practiced inside an organization.
What helps:
Asking specific operational confidentiality questions before selecting a toll partner, not after. What the partner's existing client base looks like in terms of competitive overlap. How formulation information is handled inside the facility -- who sees it, how it is stored, what happens to it after a production program ends. The most meaningful indicator is track record: how long a partner has maintained confidential relationships, and whether their clients have found them trustworthy over time.
What Successful Scale-Up Engagements Have in Common
The challenges above are not primarily chemistry problems.The issues described here are harder to see in advance because they sit in the spaces between process steps -- in documentation gaps, supply chain transitions, knowledge that was never written down, and quality methods that were never formally aligned.
The teams that navigate scale-up most reliably share a few common practices. They treat the production specification as a distinct document from the development specification, written to reflect what commercial equipment can deliver. They plan explicitly for the handoffs in their process chain, not just the steps. They stress-test formulations against input variability before committing to a full run. They transfer process knowledge in conversation, not just in documentation. And they choose partners who can engage with those details, not just execute a spec.
None of this eliminates scale-up risk. It reduces the probability of encountering the most disruptive problems at the stage where the options for recovery are most constrained.
How Valentine Chemicals Supports the Transition
For manufacturers working on liquid-to-powder conversions, polymer reactions, or custom blending programs, the toll partner you choose has a direct effect on how many of these challenges you encounter and how quickly they can be resolved when they do.
Valentine Chemicals is a fourth-generation, family-owned business based in Lockport, Louisiana, with continuous operations since 1938 and a focus on contract manufacturing since 1989. Our facility handles liquid synthesis, spray drying, drum drying, custom blending, and packaging under one roof -- which means the vendor handoff risks described above can often be avoided.
Our quality control lab is physically adjacent to production, so process decisions can be made in real time. And our client relationships -- many of them spanning decades -- reflect a confidentiality practice that goes well beyond standard NDAs.
We also work with pilot-scale and commercial-scale drying equipment on the same site, which allows formulations to be tested and refined in equipment that is geometrically representative of production, rather than translating results across different facilities.
If you are working through a scale-up program and want to understand how Valentine approaches the transition from pilot to commercial production, we would be glad to start a conversation
Explore Valentine's pilot-to-production toll manufacturing services